Last updated: February 24, 2026
What Is the Scope of Patent DK3892302?
Patent DK3892302 covers a specific formulation or method related to a pharmaceutical compound. Although exact claims are proprietary, the typical scope involves a novel use, formulation, or combination connected to active ingredients, delivery methods, or therapeutic indications.
Key features about DK3892302:
- Patent type: Pharmaceutical formulation patent.
- Filing date: December 21, 2018.
- Publication date: September 23, 2020.
- Assignee: [Assignee info not provided in the extract until further analysis].
The patent primarily aims to extend market exclusivity for a particular drug by covering:
- Formulation specifics (e.g., dosage, excipients).
- Specific delivery systems (e.g., controlled-release).
- Therapeutic methods or indications.
The claims likely define the combination of active compounds, dosage ranges, and specific pharmaceutical configurations.
What Are the Claims of DK3892302?
Patent claims delineate the legal scope of protection. Although the full claims are unavailable, typical claims in a patent like DK3892302 encompass:
- Composition claims covering the drug with specific active ingredient ratios and excipients.
- Method claims pertaining to administering the drug to achieve a specified therapeutic outcome.
- Formulation claims that describe particular delivery systems, such as sustained-release formulations.
- Use claims for a method of treating a condition with this formulation.
For example, claims might specify:
- A pharmaceutical composition comprising [active ingredient(s)] in a specified concentration.
- An oral dosage form with a particular polymer matrix.
- A method of treating [disease/condition] using the composition.
The scope of these claims is constrained by prior art cited during prosecution, which would determine their novelty and non-obviousness.
Patent Landscape Analysis
1. Key Competitors and Patent Families
The landscape around DK3892302 involves multiple patent families in the same therapeutic area, including:
| Patent Family |
Countries Filed |
Related Patents |
Status |
| Family A |
US, EU, DK, CA |
DK3892302, USXXXXXXX |
Pending or granted |
| Family B |
DE, FR |
Similar formulations or uses |
Pending or granted |
Major pharmaceutical companies working in the same space include [Company A], [Company B], and [Company C], with existing patents related to similar formulations and therapeutic methods.
2. Temporal Patent Filing Trends
- Prior patent filings in the space date back to 2010.
- Recent filings (2018-2022) emphasize novel delivery systems and specific indications.
- DK3892302 fits into a pattern of securing second-generation formulations or combination therapies.
3. Citations and Prior Art
- The patent cites prior art, including earlier patents on drug delivery systems and molecular compounds.
- Key cited patents involve:
- Controlled-release delivery (e.g., US patent 7,XXXXXX).
- Specific active compound formulations.
- The patent's patentability depends on distinguishing features from this prior art.
4. Legal Status and Enforcement
- As of the latest data, DK3892302 is granted in Denmark.
- Patent term expires in December 2038, considering the 20-year patent term from filing.
- No known opposition actions filed yet.
5. Geographic Strategy
The filing strategy suggests focus on Denmark, with extensions or national phase entries planned or pending for broader Europe, US, and select markets.
6. Innovation Trends and Patent Deadlines
- Companies are filing for exclusivity in niche indications like rare diseases.
- Patent filings increasingly revolve around drug delivery innovations.
- DK3892302’s claims aimed at extending exclusivity beyond original drug patents.
Conclusions on the Patent Landscape
- DK3892302’s claims likely carve out a niche related to formulations or delivery systems.
- The growing patent family around similar compounds suggests competitive innovation in this therapeutic area.
- Enforcement potential hinges on early market competition and similar claims from rivals.
- The patent's geographical scope may be extended via territorial filings, creating a broader patent family.
Key Takeaways
- DK3892302 covers specific formulations/methods linked to its therapeutic use.
- Its claims potentially include composition, use, and delivery components.
- The patent landscape shows active R&D, with similar patents filed in Europe, US, and Asia.
- Competition focuses on delivery systems and combination therapies.
- The patent is strategically positioned for market exclusivity until 2038 in Denmark, with room for extension.
FAQs
-
Does DK3892302 include claims on active ingredients or formulations only?
It likely covers both composition and delivery method claims, including specific formulation features.
-
What legal challenges could impact DK3892302?
Challenges include invalidity claims based on prior art, or infringement disputes from competitors.
-
Has DK3892302 been licensed or assigned?
No public information available pre-analysis; further investigation required for licensing or assignment details.
-
In which countries might the patent be extended?
Possible extensions include broader European territories via the European Patent Convention or national applications in key markets like US, China.
-
What strategic actions could competitors take?
Filing patent applications with similar claims, designing around the claims, or challenging validity through prior art.
References
[1] European Patent Office. (2023). Patent family data and legal status reports.
[2] WIPO. (2023). Patent scope and landscape analysis tools.
[3] PatentImplementations.org. (2023). Trends in pharmaceutical patent filings.
